Authors: Peters, Inga | Merseburger, Axel S. | Tezval, Hossein | Lafos, Marcel | Tabrizi, Pouriya Faraj | Mazdak, Mehrdad | Wolters, Mathias | Kuczyk, Markus A. | Serth, Jürgen | von Klot, Christoph-A.J.
Introduction: DNA methylation is an epigenetic event that occurs in normal tissues but changes in both the early and late stages of multiple tumor entities, including renal cell cancer (RCC). Many studies have shown that DNA methylation markers are relevant to RCC prognosis, but none of these markers have entered into clinical routine. Furthermore, because of its potential reversibility, DNA methylation might provide a new target for RCC therapy strategies. Materials and methods: Following PRISMA guidelines, we performed a systematic literature search up to February 2019. After selection for eligibility, a total of 56 studies were identified for
…analysis. Each study was categorized and the level of evidence assessed. Only articles reporting on DNA methylation markers and their association with survival were included. Descriptive statistical analyses were conducted with R statistical software. Results: We identified promoter methylation of SFRP1 , GATA5 , NEFH , GREM1 , and BCN1 as associated with survival in RCC. Moreover, we found evidence that methylation signatures, i.e., grouping of different potential gene markers, might be of better prognostic value than single gene marker investigations. Nevertheless, because of the heterogeneous features of the studies in terms of design, methodology, patient cohorts, and statistics, the true clinical impact of these methylation markers for prognosis in RCC patients remains uncertain. Conclusion: This systematic review elucidates the potential impact of DNA methylation on survival of patients with RCC. Several promising prognostic markers, especially methylation signatures, were identified, which is encouraging, but prospective validations are necessary to establish their true clinical value.
Keywords: DNA methylation, kidney cancer, renal cell carcinoma, prognosis, survival, biomarkers, outcome
Citation: Kidney Cancer,
vol. 4, no. 1, pp. 3-13, 2020